ZTS Zoetis
Dominant animal-health franchise priced as if it will shrink; modest mid-single-digit growth makes it cheap.
The business
Zoetis is the world's largest animal health company. It discovers, makes, and sells medicines, vaccines, parasiticides, dermatology drugs, and diagnostics for pets (about two-thirds of revenue) and livestock, selling mostly through veterinarians. Revenue repeats because pets and herds need treatment every year, vets stick with brands they trust, and patent-protected franchises like Simparica, Apoquel/Cytopoint, and Librela/Solensia earn high prices.
Quality gate · 90/100
Moat & management
| Moat | wide moat |
| Source | intangible |
| Trajectory | stable |
| Management | adequate |
Several things protect Zoetis together: patents and regulatory approvals, the largest vet-facing sales force, long-standing trust with vets, and a broad portfolio that generics struggle to copy because animal health is fragmented and brand-loyal. The moat is under real pressure in dermatology (Elanco's Zenrelia/Numelvi) and from Librela safety and label concerns. Those dents hit specific franchises; the overall franchise is still intact.
Management reinvests about 7% of sales in R&D at high returns and has shrunk the share count about 3% a year. They are now buying back stock at depressed prices, but partly with borrowed money, and they misjudged the Librela launch and the competitive response in dermatology.
Owner-earnings inputs
| Owner earnings (TTM) | 2.32B |
| Owner-earnings yield | 7.8% |
| Free-cash-flow yield | 7.8% |
| Growth used (normalized) | 3.9% |
| Market-implied growth (reverse DCF) | -2.1% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 2.41B | 3.9% | 2.21B |
| 2 | 2.50B | 3.8% | 2.10B |
| 3 | 2.59B | 3.8% | 2.00B |
| 4 | 2.69B | 3.7% | 1.90B |
| 5 | 2.79B | 3.6% | 1.81B |
| 6 | 2.88B | 3.6% | 1.72B |
| 7 | 2.99B | 3.5% | 1.63B |
| 8 | 3.09B | 3.4% | 1.55B |
| 9 | 3.19B | 3.4% | 1.47B |
| 10 | 3.30B | 3.3% | 1.39B |
| 11 | 3.41B | 3.3% | 1.32B |
| 12 | 3.52B | 3.2% | 1.25B |
| 13 | 3.63B | 3.1% | 1.18B |
| 14 | 3.74B | 3.1% | 1.12B |
| 15 | 3.85B | 3.0% | 1.06B |
Key risks
- Elanco JAK and other entrants take dermatology share and pricing in Apoquel/Cytopoint
- Librela/Solensia safety label changes limit growth of the monoclonal-antibody pain franchise
- Fewer vet visits and pet owners cutting spending, plus rising leverage from debt-funded buybacks
Catalysts
- Dermatology and pain franchises stabilize, and the pipeline (long-acting mAbs, renal, oncology) delivers
- Buybacks at around 11x FCF meaningfully raise owner earnings per share
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~-2%/yr owner-earnings growth over 15y (reverse DCF); model credits 4%. Capped at market + 6pts. · Cheap, but still in a downtrend (down (-26% vs 200-DMA, 6m -40%)) — waiting for the trend to turn before buying (don't catch a falling knife).